drugset / Trial / NCT05140187
CMV-TCR-T Cells for CMV Infection After Allogenic HSCT
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after allogenic HSCT.
Timeline
- Start
- 2021-10-15
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Publications
- Tang J, Wen Y, Yang T, Liu Q, Li F, Wang L, Gu Z, Wu Y, Luan S, Ma C, Wei Y, Qian K, Dou L, Liu D. CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial. Front Immunol. 2026 May 14;17:1820399. doi: 10.3389/fimmu.2026.1820399. eCollection 2026.
- Ma C, Chen P, Du J, Wang L, Lu N, Sun J, Qilong X, Wang Y, Dou L, Liu DH. Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation. J Immunother Cancer. 2024 Jan 6;12(1):e007735. doi: 10.1136/jitc-2023-007735.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMV-TCR-T cells | Cell therapy | 1000 cells/kg | — |
| Subject | CMV-TCR-T cells | Cell therapy | 100000 cells/kg | — |
| Subject | CMV-TCR-T cells | Cell therapy | 500000 cells/kg | — |